Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on March 27th, 2018 by Tim HoctorPharma R&D
At first glance, companies using wearables, such as Fitbits, as a way of encouraging health and wellness among employees may seem like a great idea. Healthier workers are typically happier workers, Continue reading “Can Wearables Improve Employee Health?” »
Posted on March 27th, 2018 by Christy J. WilsonPharma R&D
As big pharmaceutical companies struggle to get enough value for their R&D dollars in today’s challenging innovation landscape, small pharmas and biotech startups have come to play a crucial role in the drug discovery process. Continue reading “Helping Startups in the Pursuit of Drug Discovery Success” »
Posted on February 23rd, 2018 by Neal KatzPharma R&D
“Complex” is the term that best describes the conditions that affect us. Whether it’s a disease or a consequence of a natural process such as aging, there are no simple fixes. Continue reading “To streamline early discovery, a cross-disciplinary, data-driven workflow process is key” »
Posted on February 14th, 2018 by Betsy DavisThe Hive
In 2017, Elsevier introduced a new program called The Hive, an innovation initiative for biotech and pharmaceutical start-ups committed to promoting collaboration and inspiration across the Pharma & Life Sciences industry.
Posted on February 12th, 2018 by Christy J. WilsonPharma R&D
Today’s big data has the power to drive innovation in ways that the pharmaceutical industry could previously only dream of. Yet harnessing that power comes with an equally sizable challenge: it will require an enormous shift in how research is performed. Continue reading “Harnessing big data — it’s challenging, but it can be done” »
Posted on February 9th, 2018 by Xuanyan XuPharmacovigilance
A key component of any pharmacovigilance strategy is building search strings that successfully identify potential adverse events, which must be reported to regulatory agencies. If the query returns too narrow a result set, adverse events may be missed. Continue reading “In pharmacovigilance, effective search strings are key” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.